Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Work In Process: 2017-2025

Historic Work In Process for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $29.2 million.

  • Ultragenyx Pharmaceutical's Work In Process rose 43.92% to $29.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 million, marking a year-over-year increase of 43.92%. This contributed to the annual value of $22.0 million for FY2024, which is 16.48% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Work In Process is $29.2 million, which was up 47.75% from $19.8 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Work In Process peaked at $29.2 million during Q3 2025, and registered a low of $6.8 million during Q1 2021.
  • Moreover, its 3-year median value for Work In Process was $20.3 million (2024), whereas its average is $21.3 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Work In Process skyrocketed by 76.75% in 2022 and then dropped by 21.77% in 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Work In Process (Quarterly) stood at $10.5 million in 2021, then soared by 66.47% to $17.5 million in 2022, then increased by 7.85% to $18.9 million in 2023, then rose by 16.48% to $22.0 million in 2024, then soared by 43.92% to $29.2 million in 2025.
  • Its last three reported values are $29.2 million in Q3 2025, $19.8 million for Q2 2025, and $22.9 million during Q1 2025.